ASCO 2026 Prostate Cancer Updates: TALAPRO-3, PROTEUS, & Earlier Intervention

The treatment paradigm for advanced prostate cancer is undergoing a major shift—bringing highly effective, targeted therapies into earlier disease settings to improve long-term outcomes while balancing long-term treatment burden. This discussion serves as a faculty follow-up to Dr. Freedland's i3 Health Virtual Tumor Board, Navigating Treatment Selection and Sequencing in Metastatic Prostate Cancer. Read the full accompanying article on Oncology Data Advisor: 👉 https://oncdata.com/prostate-cancer-faculty-follow-up In this interview, expert faculty discusses practice-changing updates presented at the 2026 ASCO Annual Meeting. Highlighting key results from the phase 3 TALAPRO-3 and PROTEUS trials, Dr. Freedland explores how PARP inhibition and perioperative androgen receptor pathway inhibitors (ARPIs) are expanding treatment options across both metastatic hormone-sensitive prostate cancer (mHSPC) and high-risk localized disease. What You’ll Learn in This Episode: 🔹 TALAPRO-3 Trial Insights: How talazoparib plus enzalutamide demonstrated broad-based benefit in HRR-altered mHSPC, including unexpected activity in ATM-mutated tumors. 🔹 PROTEUS Trial Findings: Evaluating perioperative apalutamide plus ADT in high-risk localized prostate cancer to achieve a 20% reduction in metastasis/death risk and a 35% reduction in the need for subsequent salvage therapies. 🔹 Moving Effective Therapies Earlier: Exploring the defining clinical trend of shifting PARP inhibitors and ARPIs into earlier disease settings to achieve durable control through finite treatment. 🔹 The Role of Biomarkers & Imaging: Leveraging genomic testing and prostate-specific membrane antigen (PSMA) imaging to identify aggressive disease sooner and personalize shared decision-making. 🔹 Next-Generation Targets: A look ahead at emerging therapeutic modalities, including T-cell engagers and androgen receptor degraders.